Spyre Therapeutics (SYRE) Capital Expenditures (2015 - 2023)
Spyre Therapeutics posted quarterly Capital Expenditures of -$2.1 million for Q3 2023, down 206800.0% year-on-year from N/an in Q3 2022, and down 206800.0% on a QoQ basis from $1000.0 in Q3 2022.
Spyre Therapeutics (SYRE) has 9 years of Capital Expenditures data on file, last reported at -$2.1 million in Q3 2023.
- For the quarter ending Q3 2023, Capital Expenditures fell 206800.0% year-over-year to -$2.1 million; the trailing twelve-month figure through Dec 2023 stood at -$2.1 million (down 5536.84% YoY), and the FY2022 full-year result was $38000.0, down 93.37% from the prior year.
- Capital Expenditures for Q3 2023 stood at -$2.1 million, down from $1000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.8 million in Q3 2020 and bottomed at -$2.1 million in Q3 2023.
- The 5-year median for Capital Expenditures is $87500.0 (2019), against an average of $227142.9.
- The widest annual swing landed in 2020, when Capital Expenditures jumped 2531.58%; it then plunged 206800.0% in 2023.
- A 5-year view of Capital Expenditures shows it stood at $38000.0 in 2019, then surged by 2531.58% to $1.0 million in 2020, then sank by 45.0% to $550000.0 in 2021, then plunged by 99.82% to $1000.0 in 2022, then slumped by 206800.0% to -$2.1 million in 2023.
- The last three Capital Expenditures figures came in at -$2.1 million (Q3 2023), $1000.0 (Q3 2022), and $37000.0 (Q1 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -2.07 Mn |
| Sep 30, 2023 | -2.07 Mn |
| Sep 30, 2022 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Sep 30, 2021 | 550,000.00 |
| Sep 30, 2021 | 550,000.00 |
| Jun 30, 2021 | -427,000.00 |
| Jun 30, 2021 | -427,000.00 |
| Mar 31, 2021 | 450,000.00 |
| Mar 31, 2021 | 450,000.00 |
| Dec 31, 2020 | 1.00 Mn |
| Dec 31, 2020 | 1.00 Mn |
| Sep 30, 2020 | 2.84 Mn |
| Sep 30, 2020 | 2.84 Mn |
| Jun 30, 2020 | -617,000.00 |
| Jun 30, 2020 | -617,000.00 |
| Mar 31, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.06 Mn |
| Dec 31, 2019 | 38,000.00 |
| Dec 31, 2019 | 38,000.00 |
| Sep 30, 2019 | 143,000.00 |
| Sep 30, 2019 | 143,000.00 |
| Jun 30, 2019 | 57,000.00 |
| Jun 30, 2019 | 57,000.00 |
| Mar 31, 2019 | 118,000.00 |
| Mar 31, 2019 | 118,000.00 |
| Dec 31, 2018 | 203,000.00 |
| Dec 31, 2018 | 203,000.00 |
| Sep 30, 2018 | 101,000.00 |
| Sep 30, 2018 | 101,000.00 |
| Jun 30, 2018 | 35,000.00 |
| Jun 30, 2018 | 35,000.00 |
| Mar 31, 2018 | 83,000.00 |
| Mar 31, 2018 | 83,000.00 |
| Dec 31, 2017 | -371,000.00 |
| Dec 31, 2017 | -371,000.00 |
| Sep 30, 2017 | 111,000.00 |
| Sep 30, 2017 | 111,000.00 |
| Jun 30, 2017 | 46,000.00 |
| Jun 30, 2017 | 46,000.00 |
| Mar 31, 2017 | 271,000.00 |
| Mar 31, 2017 | 271,000.00 |
| Dec 31, 2016 | 121,000.00 |
| Dec 31, 2016 | 121,000.00 |
| Jun 30, 2016 | 89,000.00 |
| Jun 30, 2016 | 89,000.00 |
| Mar 31, 2016 | 2,000.00 |
| Mar 31, 2016 | 2,000.00 |
| Dec 31, 2015 | 40,000.00 |
| Dec 31, 2015 | 40,000.00 |
| Sep 30, 2015 | 98,000.00 |
| Sep 30, 2015 | 98,000.00 |
| Jun 30, 2015 | 6,000.00 |
| Jun 30, 2015 | 6,000.00 |
| Mar 31, 2015 | 64,000.00 |
| Mar 31, 2015 | 64,000.00 |